Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Fig. 2

Significant down-regulation of hsa-miR-181a-5p as shown by an arrow when Group 2 (CML patients non-responsive to imatinib therapy); was compared with the Control Group (blood donors). In addition, the other two arrows showed significant up-regulation of hsa-miR-26a-5p and hsa-miR-182-5p

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us